Venrock Healthcare Capital Partners III, L.P. 13D and 13G filings for Taysha Gene Therapies, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:51 pm Sale | 2024-09-30 | 13G | Taysha Gene Therapies, Inc. TSHA | Venrock Healthcare Capital Partners III, L.P. | 9,000,000 4.400% | -1,412,872 (-13.57%) | Filing |
| 2024-02-14 8:44 pm Sale | 2023-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA | Venrock Healthcare Capital Partners III, L.P. | 10,412,872 5.600% | -4,031,572 (-27.91%) | Filing |
| 2023-08-28 4:16 pm Purchase | 2023-08-16 | 13G | Taysha Gene Therapies, Inc. TSHA | Venrock Healthcare Capital Partners III, L.P. | 14,444,444 7.700% | 14,444,444 (New Position) | Filing |